Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial.

Autor: Martinez J; Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY. Electronic address: martinej78@nychhc.org., Subramanian K; Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY., Huicochea Castellanos S; Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY., Thomas C; Division of Biostatistics and Epidemiology, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY., Choudhury AR; Division of Biostatistics and Epidemiology, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY., Muench B; Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY., Tagawa ST; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY., Pillarsetty NVK; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY., Osborne JR; Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY.
Jazyk: angličtina
Zdroj: Translational oncology [Transl Oncol] 2023 Feb; Vol. 28, pp. 101593. Date of Electronic Publication: 2022 Dec 24.
DOI: 10.1016/j.tranon.2022.101593
Abstrakt: The clinical utility of gallium 68 ( 68 Ga)-PSMA PET for the diagnosis and management of prostate cancer is driven in part by radioisotope availability and production costs. This study evaluates the equivalence between the two manufacturing processes for 68 Ga-PSMA: 68 Ga-PSMA-cyclotron (from a solid target) and 68 Ga-PSMA-generator. A prospective, single-arm, single-institution non-randomized study was conducted where 16 patients with prostate adenocarcinoma underwent PET/CTs consecutively within 12 to 48 hours with each type of manufactured 68 Ga-PSMA between December 2020 and June 2021. The intraclass correlation coefficients suggested acceptable reliability in all lesion parameters (ICC > 0.70). Bland-Altman analysis demonstrated acceptable bias levels for all lesion parameters. Thereby 68 Ga-cyclotron (solid target) and 68 Ga-generator production methods tagged to the same PSMA ligand resulted in scans which were deemed to be equivalent in detecting PSMA+ lesions in our study. As cyclotron-produced, solid- target 68 Ga can be made in large (Ci) quantities, it is a promising tool for future application in 68 Ga-PSMA PET scans with the potential to decrease radiotracer production costs and increase isotope availability.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022. Published by Elsevier Inc.)
Databáze: MEDLINE